volume 2, issue 8, PS394 2007
DOI: 10.1097/01.jto.0000283259.15347.56
View full text
|
|
Share

Abstract: Background: Platinum-based chemotherapy (CT) for previously untreated advanced NSCLC improves survival (OS) and QoL but can have considerable toxicity. Erlotinib (E) (Tarceva ® ), an oral EGFR inhibitor, improves OS and progression-free survival (PFS) in 2nd-and 3rd-line treatment of NSCLC with acceptable toxicity, similar response and OS to chemotherapy, and a suggestion that pts whose tumors express EGFR might benefit most. In unselected CT-naïve NSCLC pts, adding daily E to concurrent CT did not improve out…

Expand abstract

Search citation statements

Order By: Relevance

Citation Types

0
1
0

Paper Sections

0
0
0
0
0

Publication Types

0
0
0
0

Relationship

0
0

Authors

Journals